2019 Future of Multiple System Atrophy (MSA) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

February 2019 | 50 pages | ID: 24997CF7B0BEN
VPAResearch

Abstracts

The global demand for Multiple System Atrophy (MSA) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Multiple System Atrophy (MSA) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Multiple System Atrophy (MSA) pipeline companies from advancing their products into Phase 3 or Phase 4.

Multiple System Atrophy (MSA) Report Description-

The 2019 pipeline study on Multiple System Atrophy (MSA) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Multiple System Atrophy (MSA) pipeline compounds.

The Multiple System Atrophy (MSA) pipeline guide presents information on all active drugs currently being developed for Multiple System Atrophy (MSA). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Multiple System Atrophy (MSA) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Multiple System Atrophy (MSA) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Multiple System Atrophy (MSA) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Multiple System Atrophy (MSA) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Multiple System Atrophy (MSA) pipeline report includes-

• An overview of Multiple System Atrophy (MSA) disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of Multiple System Atrophy (MSA) pipeline
• Company wise list of Multiple System Atrophy (MSA) pipeline
• Mechanism of Action wise Multiple System Atrophy (MSA) pipeline
• For each pipeline candidate, the following details are provided
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials/Results
• Company Overview and Recent Developments

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Multiple System Atrophy (MSA) pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Multiple System Atrophy (MSA) pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into companies participating in Multiple System Atrophy (MSA) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL MULTIPLE SYSTEM ATROPHY (MSA) PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. EXECUTIVE SUMMARY

3.1 Multiple System Atrophy (MSA) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
  3.2.1 Pre-clinical
  3.2.2 Discovery
  3.2.3 Phase
  3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
  3.3.1 Phase
  3.3.2 Pre-registration
3.4 Companies involved in Multiple System Atrophy (MSA) pipeline, H1- 2019
3.5 Mechanism of Action wise Multiple System Atrophy (MSA) Pipeline Candidates

4 AFFIRIS AG MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

4.1 AFFiRiS AG Business Profile
4.2 AFFiRiS AG Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
4.3 Drug Snapshot
  4.3.1 Originator
  4.3.2 Collaborator/Co-Developer
  4.3.3 Route of Administration
  4.3.4 Orphan Drug/Fast Track/Special Designation
  4.3.5 Geography
  4.3.6 Type of Molecular Entity
  4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

5.1 Biohaven Pharmaceutical Holding Company Business Profile
5.2 Biohaven Pharmaceutical Holding Company Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
5.3 Drug Snapshot
  5.3.1 Originator
  5.3.2 Collaborator/Co-Developer
  5.3.3 Route of Administration
  5.3.4 Orphan Drug/Fast Track/Special Designation
  5.3.5 Geography
  5.3.6 Type of Molecular Entity
  5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 CORESTEM INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

6.1 Corestem Inc Business Profile
6.2 Corestem Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
6.3 Drug Snapshot
  6.3.1 Originator
  6.3.2 Collaborator/Co-Developer
  6.3.3 Route of Administration
  6.3.4 Orphan Drug/Fast Track/Special Designation
  6.3.5 Geography
  6.3.6 Type of Molecular Entity
  6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 DENALI THERAPEUTICS INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

7.1 Denali Therapeutics Inc Business Profile
7.2 Denali Therapeutics Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
7.3 Drug Snapshot
  7.3.1 Originator
  7.3.2 Collaborator/Co-Developer
  7.3.3 Route of Administration
  7.3.4 Orphan Drug/Fast Track/Special Designation
  7.3.5 Geography
  7.3.6 Type of Molecular Entity
  7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 ENTERIN INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

8.1 Enterin Inc Business Profile
8.2 Enterin Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
8.3 Drug Snapshot
  8.3.1 Originator
  8.3.2 Collaborator/Co-Developer
  8.3.3 Route of Administration
  8.3.4 Orphan Drug/Fast Track/Special Designation
  8.3.5 Geography
  8.3.6 Type of Molecular Entity
  8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 ICB INTERNATIONAL INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

9.1 ICB International Inc Business Profile
9.2 ICB International Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
9.3 Drug Snapshot
  9.3.1 Originator
  9.3.2 Collaborator/Co-Developer
  9.3.3 Route of Administration
  9.3.4 Orphan Drug/Fast Track/Special Designation
  9.3.5 Geography
  9.3.6 Type of Molecular Entity
  9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 INHIBIKASE THERAPEUTICS MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

10.1 Inhibikase Therapeutics Business Profile
10.2 Inhibikase Therapeutics Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
10.3 Drug Snapshot
  10.3.1 Originator
  10.3.2 Collaborator/Co-Developer
  10.3.3 Route of Administration
  10.3.4 Orphan Drug/Fast Track/Special Designation
  10.3.5 Geography
  10.3.6 Type of Molecular Entity
  10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 MITODYS THERAPEUTICS LTD MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

11.1 MitoDys Therapeutics Ltd Business Profile
11.2 MitoDys Therapeutics Ltd Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
11.3 Drug Snapshot
  11.3.1 Originator
  11.3.2 Collaborator/Co-Developer
  11.3.3 Route of Administration
  11.3.4 Orphan Drug/Fast Track/Special Designation
  11.3.5 Geography
  11.3.6 Type of Molecular Entity
  11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 MODAG GMBH MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

12.1 Modag GmbH Business Profile
12.2 Modag GmbH Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
12.3 Drug Snapshot
  12.3.1 Originator
  12.3.2 Collaborator/Co-Developer
  12.3.3 Route of Administration
  12.3.4 Orphan Drug/Fast Track/Special Designation
  12.3.5 Geography
  12.3.6 Type of Molecular Entity
  12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 NEUROPORE THERAPIES INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

13.1 Neuropore Therapies Inc Business Profile
13.2 Neuropore Therapies Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
13.3 Drug Snapshot
  13.3.1 Originator
  13.3.2 Collaborator/Co-Developer
  13.3.3 Route of Administration
  13.3.4 Orphan Drug/Fast Track/Special Designation
  13.3.5 Geography
  13.3.6 Type of Molecular Entity
  13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 PRANA BIOTECHNOLOGY LTD MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

14.1 Prana Biotechnology Ltd Business Profile
14.2 Prana Biotechnology Ltd Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
14.3 Drug Snapshot
  14.3.1 Originator
  14.3.2 Collaborator/Co-Developer
  14.3.3 Route of Administration
  14.3.4 Orphan Drug/Fast Track/Special Designation
  14.3.5 Geography
  14.3.6 Type of Molecular Entity
  14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15 UNITED NEUROSCIENCE INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

15.1 United Neuroscience Inc Business Profile
15.2 United Neuroscience Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
15.3 Drug Snapshot
  15.3.1 Originator
  15.3.2 Collaborator/Co-Developer
  15.3.3 Route of Administration
  15.3.4 Orphan Drug/Fast Track/Special Designation
  15.3.5 Geography
  15.3.6 Type of Molecular Entity
  15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16. LATEST MULTIPLE SYSTEM ATROPHY (MSA) DRUG PIPELINE DEVELOPMENTS, 2019

17. APPENDIX

17.1 About Us
17.2 Sources and Methodology
17.3 Contact Information